Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IGZRX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PRO-1286
|
|||||
| Synonyms |
PRO-1286; PRO1286; GEN1286
Click to Show/Hide
|
|||||
| Organization |
ProfoundBio (Originator)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-EGFR/c-Met bsAb
|
Antibody Info | Antigen Name | |||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
T1000
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
sesutecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18; ECOG 0-1; measurable advanced solid tumors (RECIST 1.1); refractory to standard therapies; adequate organ function; willingness to provide tumor samples.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06685068 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include AE incidence (NCI-CTCAE v5.0) over 3 years 9 months and DLTs during first cycle (21 days) for GEN1286 safety evaluation.
|
||||
| Other Endpoint |
Secondary endpoints comprise efficacy measures (ORR, DCR, PFS, DOR per RECIST 1.1) and PK parameters (AUC, Cmax, Tmax, t1/2, CL, Vz, Ctrough of antibody-conjugated exatecan components) over 2 years 9 months, plus ADA assessment.
|
||||